PRIME and PRIME2 assessed the effect of DUPIXENT on itch improvement, as well as its effect on PN lesions.1,2

  • ≈3x as many patients had significantly reduced itch (as measured by ≥4-point improvement in WI-NRS) in PRIME at Week 24 (60%
    with DUPIXENT vs 18% with placebo; P<0.0001)
  • ≈2.5x as many patients achieved significant nodule clearance in PRIME at Week 24 (48% with DUPIXENT vs 18% with placebo; P=0.0004)
PRIME2
  • 37% of DUPIXENT patients achieved a meaningful response at Week 12 vs 22% with placebo; P=0.0216 [primary endpoint]. At Week 24, 58% of DUPIXENT patients achieved significant itch relief vs 20% with placebo; P<0.0001 [secondary endpoint]
  • 45% of DUPIXENT patients similarly achieved significant nodule clearance (IGA PN-S 0 or 1) at Week 24 vs 16% with placebo; P<0.0001 [secondary endpoint]

WI-NRS Results

IGA PN-S RESULTS

Demonstrated safety profile
  • Most common adverse reactions (≥2%) were nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea1
  • No patients treated with DUPIXENT discontinued the study due to AEs vs 3% with placebo1
    • Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs or until a parasitic (helminth) infection resolves in a patient who does not respond to anti-helminth treatment

SAFETY DATA

IGA PN-S, Investigator’s Global Assessment PN-Stage; WI-NRS, Worst Itch Numeric Rating Scale.

Dosage and Administration

Thinking about prescribing DUPIXENT? Find the information you need to get started.
Explore administration Options